



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Cwm Taf Morgannwg
University Health Board



Freedom of Information Request: Our Reference CTMUHB_200_24

You asked:

NICE have announced TA943 supporting Hybrid Closed Loop systems in people living with T1 diabetes to have access to this technology. NHS England have asked ICBs to set out their plans on how they are going to deliver this.

Please note Cwm Taf Morgannwg University Health Board is not an ICB governed by NHS England. We are a Health Board in Wales, governed by NHS Wales (Welsh Government).

However, we can confirm that Cwm Taf Morgannwg University Health Board (CTMUHB) recognises and accepts the NICE Hybrid Closed Loop (HCL) Technology Appraisal (TA943), and will aim to deliver its recommendations in full.

1. When is the ICB going to implement NICE TA943 and if not what would be the reason for not doing so?

Cwm Taf Morgannwg University Health Board (CTMUHB) is in the process of implementing NICE TA943 and aims to adopt the Diabetes Network Wales (DNW) delivery policy currently being developed and agreed by the DNW Hybrid Closed Loop sub-group. This group recognises that access will be delivered over a 5-year phased roll out in NHS England, and has already established a priority group for HCL initiation in year 1 for Wales. Successful and sustainable delivery of the HCL system will require the development and agreement of business cases for both the HCL technology, and the staff required to initiate and subsequently provide ongoing care and management for people on this technology.

2. What policy is currently in place within the ICB for use of Hybrid Closed Loop Systems?

CTMUHB currently initiates HCL systems across each of its 3 DGH sites based on the existing NICE guidelines for insulin pump therapy and Continuous glucose monitoring, as per updated NICE guidance NG17 in 2022.

3. When does the ICB plan to have a policy in place in line with TA943

CTMUHB is in the process of writing business cases for 2024/25 outlining the number of units required to deliver HCL technology to the prioritised group, as well as a case for the diabetes healthcare professional establishment required to initiate and provide sustainable long term care to this group.

- 4. Will this policy promote patient choice - drawing your attention to NICE FAQ document on local formularies and ensuring that full choice of TA treatments is not restricted**
<https://www.nice.org.uk/Media/Default/About/what-we-do/NICE-guidance/NICE-technology-appraisals/Frequently-asked-questions-on-NICE-compliance.pdf>

CTMUHB will continue to offer a choice of sensor augmented pump therapy choices to people with diabetes

- 5. Please can you also share a copy of the implementation plan that was submitted to NHS England**

Not applicable.